http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106519027-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-70 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1018 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42 |
| filingDate | 2016-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106519027-B |
| titleOfInvention | The full human monoclonal antibody 5J13 of anti-H7N9 and its preparation method and application |
| abstract | The present invention relates to the full human monoclonal antibody 5J13 of anti-H7N9 and its preparation method and application, the amino acid sequence in the area heavy and light chain CDR1, CDR2 and CDR3 of the antibody is respectively the area heavy chain CDR1: GFSFSNYG；The area heavy chain CDR2: ISYDGTNK；The area heavy chain CDR3: AKGRGPYCSSSICYHGMDV；The area light chain CDR1: QSVLSGSINMNY；The area light chain CDR2: WAS；The area light chain CDR3: QQYYSTPLT.Antibody of the present invention can target the hemagglutinin HA in conjunction with H7N9 virus, have the neutralization activity of anti-H7N9 virus infection significantly；Compared to source of mouse antibody, the gene of human antibody is entirely derived from the gene of people, and without the ingredient of other kinds, the toxic side effects such as anti-mouse antiantibody do not occur, has better biocompatibility, is more suitable for and more potential as the macromolecular drug for treating influenza virus. |
| priorityDate | 2016-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 415.